Song, Yuqin
Zhou, Hui
Zhang, Huilai
Liu, Wei
Shuang, Yuerong
Zhou, Keshu
Lv, Fangfang
Xu, Hao
Zhou, Jianfeng
Li, Wei
Wang, Huaqing
Zhang, Hongyu
Huang, Haiwen
Zhang, Qingyuan
Xu, Wei
Ge, Zheng
Xiang, Ying
Wang, Shuye
Gao, Da
Yang, Shun’e
Lin, Jinying
Wang, Lin
Zou, Liqun
Zheng, Meifang
Liu, Jing
Shao, Zonghong
Pang, Ying
Xia, Ruixiang
Chen, Zhendong
Hou, Ming
Yao, Hongxia
Feng, Ru
Cai, Zhen
Zhang, Mingzhi
Ran, Wenhua
Liu, Lin
Zeng, Shan
Yang, Wei
Liu, Peng
Liang, Aibin
Zuo, Xuelan
Zou, Qingfeng
Ma, Junxun
Sang, Wei
Guo, Ye
Zhang, Wei
Cao, Yongqing
Li, Yan
Feng, Jifeng
Du, Xin
Zhang, Xiaohong
Zhao, Hongguo
Zhou, Hui
Yu, Jie
Sun, Xing
Zhu, Jun
Qiu, Lugui
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 Trial
https://doi.org/10.1007/s12325-020-01603-8
Funding for this research was provided by:
This study was funded by Innovent Biologics and co-funded by Eli Lilly and Company. (-)
Article History
Received: 23 October 2020
Accepted: 9 December 2020
First Online: 9 March 2021